1. Pathological complete response and accelerated drug approval in early breast cancer;Prowell;N Engl J Med,2012
2. Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response after different types of HER2-targeted therapy: a pooled analysis;Swain,2019
3. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial;Gianni;Lancet Oncol,2016
4. Breast cancer recurrence and predictors for recurrence despite pathologic complete response following neoadjuvant chemotherapy [abstract];Borremans,2019